Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 183.45M | 215.65M | -2.07M | -10.01M | -47.58M |
| Total Depreciation and Amortization | 748.00K | 1.09M | 1.64M | 2.20M | 2.69M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -35.94M | -37.69M | 15.82M | 20.87M | 24.35M |
| Change in Net Operating Assets | -153.03M | -195.97M | -38.83M | -89.06M | -117.46M |
| Cash from Operations | -4.77M | -16.91M | -23.44M | -75.99M | -138.00M |
| Capital Expenditure | -38.00K | -179.00K | -252.00K | -253.00K | -266.00K |
| Sale of Property, Plant, and Equipment | -- | 206.00K | 1.04M | 1.05M | 1.05M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 96.62M | 90.20M | -- | -- | -- |
| Other Investing Activities | -61.16M | -1.38M | 1.66M | 73.91M | 125.21M |
| Cash from Investing | 35.42M | 88.85M | 2.45M | 74.70M | 125.99M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -80.56M | -80.56M | -22.00K | -33.00K | -40.00K |
| Issuance of Common Stock | -- | 23.00K | 23.00K | 139.00K | 139.00K |
| Repurchase of Common Stock | -69.00K | -75.00K | -174.00K | -238.00K | -354.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.40M | -5.40M | -46.00K | -46.00K | -- |
| Cash from Financing | -86.03M | -86.01M | -219.00K | -178.00K | -255.00K |
| Foreign Exchange rate Adjustments | 1.08M | 1.04M | 338.00K | 1.94M | 751.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.31M | -13.03M | -20.87M | 466.00K | -11.51M |